Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 June 2026
The European Medicines Agency has issued a positive opinion recommending the approval of Eli Lilly's Jaypirca for chronic lymphocytic leukemia.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
📍 How it ended
The Committee for Medicinal Products for Human Use issued a positive opinion regarding the expanded use of the cancer treatment Jaypirca. Following this recommendation and the submission of a marketing authorization application to the European Commission, the news coverage quieted without a definitive conclusion regarding final regulatory approval.
Epilogue added 141d ago, after coverage quieted.
The brief
The Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Jaypirca, also known as pirtobrutinib, for the treatment of adult patients with chronic lymphocytic leukemia (CLL). This recommendation covers the use of the medication across all lines of therapy.
Coverage from the European Medicines Agency, Yahoo Finance, and GuruFocus highlights the committee's decision during its June 22-25 meeting. Reports from Futu Securities note that the recommendation has prompted a submission for marketing authorization to the European Commission and resulted in stock market activity for Eli Lilly.
Future developments depend on the European Commission's final decision regarding the marketing authorization. Coverage does not yet specify a timeline for the final regulatory ruling.
Synthesized by PULSE from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 144d ago.
Quick answers
What is Jaypirca's designated use?
The CHMP recommended its approval for adult patients with chronic lymphocytic leukemia across all lines of therapy.
Who issued the recommendation?
The recommendation was issued by the Committee for Medicinal Products for Human Use (CHMP) at the European Medicines Agency.
What is the next step in the process?
The application has been submitted to the European Commission for final marketing authorization.
Coverage (14)
- Eli Lilly Stock Jumps 7% as Medicare Opens GLP-1 Access: What a $2,100 Target Means for Investors TIKR.com · 144d ago
- Eli Lilly Leads 5 Stocks Near Buy Points As The Market Rally Rotates Investor's Business Daily · 144d ago
- Why Is Eli Lilly (LLY) Stock Soaring Today Yahoo Finance · 144d ago
- Lilly Hits Record High On Massive Profit Growth, Leads 28 Just Added To Best Stock Lists Investor's Business Daily · 144d ago
- Pirtobrutinib Plus Venetoclax Shows Promising Results in CLL Oncology News Central · 144d ago
- Why Is Eli Lilly (LLY) Stock Soaring Today The Globe and Mail · 144d ago
- Eli Lilly shares rise after EU panel backs expanded use of Jaypirca Yahoo Finance · 144d ago
- Matthew Davids' Comments on the New Phase 3 Results From the BRUIN CLL-322 Trial - Dana-Farber Oncodaily · 144d ago
- Eli Lilly (LLY) Gains EMA Support for Cancer and Diabetes Treatm GuruFocus · 144d ago
- Eli Lilly (LLY) Receives Positive EMA Opinion for Jaypirca Treat GuruFocus · 144d ago
- Dr Ahn: Exploring Treatment-Free Remissions With Pirtobrutinib in CLL Targeted Oncology · 144d ago
- U.S. Stocks Move | Eli Lilly and Co (LLY.US) Rises Over 4% as Jaypirca Marketing Authorization Application Submitted to European Commission 富途牛牛 · 144d ago
- Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with chronic lymphocytic leukemia (CLL) across all lines of therapy Yahoo Finance · 144d ago
- Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 June 2026 European Medicines Agency (EMA) · 144d ago
Topics
Related trends
Versant, Lilly put $100 million behind new startup aimed at solving one of gene therapy’s thorniest issues
Seawolf Therapeutics launches with $100 million from Versant Ventures and Eli Lilly to develop non-viral gene therapies targeting obesity, muscle loss, and osteoporosis.
Makers of obesity drugs hit back at claims of negative side effects
Makers of obesity drugs defend their product safety amid mounting public scrutiny and reports of side effects.
New drug could be cure for common cause of high blood pressure
EU medicines panel recommends AstraZeneca's baxdrostat for uncontrolled hypertension, while new research suggests a potential cure for hormone-driven high blood pressure.
Former Eli Lilly rep claims she was fired for complaining about marketing of Mounjaro diabetes drug
A former Eli Lilly sales representative has filed a retaliation lawsuit alleging she was fired for objecting to Mounjaro marketing.
Eli Lilly’s Foundayo obesity pill eases sleep apnea in late-stage trial, paving way for approval
Eli Lilly's weight-loss pill Foundayo meets its main goal in a late-stage trial by easing sleep apnea.
Experimental weight-loss drug eases painful knee osteoarthritis in two clinical trials
Eli Lilly's experimental triple-hormone drug retatrutide cut knee osteoarthritis pain and produced average weight loss of roughly 25% in two Phase 3 trials involving more than 1,000 adults with obesity.